Nicolae Bacalbasa1,2, Irina Balescu3, Veronica Ilie2, Raluca Florea2, Andrei Sorop2, Vladislav Brasoveanu4, Iulian Brezean1,5, Mihaela Vilcu1,5, Simona Dima2,4, Irinel Popescu4,6. 1. "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania. 2. Center of Excellence in Translational Medicine - Fundeni Clinical Institute, Bucharest, Romania. 3. "Ponderas" Academic Hospital, Bucharest, Romania irina.balescu@ponderas-ah.ro. 4. "Dan Setlacec" Center of Gastrointestinal Disease and Liver Transplantation, Fundeni Clinical Institute, Bucharest, Romania. 5. "Ion Cantacuzino" Clinical Hospital, Bucharest, Romania. 6. "Titu Maiorescu" University, Bucharest, Romania.
Abstract
BACKGROUND/AIM: Breast cancer remains one of the most frequently encountered malignancies worldwide, which is in most cases diagnosed in early stages of disease. However, although surgery and adjuvant oncological treatment are performed with curative intent, a certain number of cases will develop distant metastases. In cases presenting oligometastatic disease, surgery might be tempted in order to maximize the benefit in terms of survival. The aim of this paper was to identify which cases could benefit most after liver resection for breast cancer liver metastases. MATERIALS AND METHODS: The study included 67 patients submitted to surgery for breast cancer liver metastases between 2003 and 2017 in the "Dan Setlacec" Center of Gastrointestinal Diseases and Liver Transplantation, Fundeni Clinical Institute. RESULTS: Patients diagnosed with hormone-positive breast tumors reported a significantly higher disease-free and overall survival after resection of the primary tumor. After resection for breast cancer liver metastases, patients presenting hormone receptors at the level of the metastatic sites also experienced a better outcome when compared to those in which hormonal receptors were absent. However, the difference was not statistically significant. CONCLUSION: Liver resection for breast cancer liver metastases seems to be associated with the best outcomes in terms of survival in patients presenting positive hormonal receptors status. Copyright
BACKGROUND/AIM: Breast cancer remains one of the most frequently encountered malignancies worldwide, which is in most cases diagnosed in early stages of disease. However, although surgery and adjuvant oncological treatment are performed with curative intent, a certain number of cases will develop distant metastases. In cases presenting oligometastatic disease, surgery might be tempted in order to maximize the benefit in terms of survival. The aim of this paper was to identify which cases could benefit most after liver resection for breast cancer liver metastases. MATERIALS AND METHODS: The study included 67 patients submitted to surgery for breast cancer liver metastases between 2003 and 2017 in the "Dan Setlacec" Center of Gastrointestinal Diseases and Liver Transplantation, Fundeni Clinical Institute. RESULTS:Patients diagnosed with hormone-positive breast tumors reported a significantly higher disease-free and overall survival after resection of the primary tumor. After resection for breast cancer liver metastases, patients presenting hormone receptors at the level of the metastatic sites also experienced a better outcome when compared to those in which hormonal receptors were absent. However, the difference was not statistically significant. CONCLUSION: Liver resection for breast cancer liver metastases seems to be associated with the best outcomes in terms of survival in patients presenting positive hormonal receptors status. Copyright
Authors: Bernard Fisher; Jong-Hyeon Jeong; Stewart Anderson; John Bryant; Edwin R Fisher; Norman Wolmark Journal: N Engl J Med Date: 2002-08-22 Impact factor: 91.245
Authors: Katrin Hoffmann; Clemens Franz; Ulf Hinz; Peter Schirmacher; Christian Herfarth; Michael Eichbaum; Markus W Büchler; Peter Schemmer Journal: Ann Surg Oncol Date: 2010-02-09 Impact factor: 5.344
Authors: Michael H R Eichbaum; Margarete Kaltwasser; Thomas Bruckner; Thomas M de Rossi; Andreas Schneeweiss; Christof Sohn Journal: Breast Cancer Res Treat Date: 2006-03 Impact factor: 4.872
Authors: Dominique Elias; Franck Maisonnette; Michel Druet-Cabanac; Jean Francois Ouellet; Jean Marc Guinebretiere; Marc Spielmann; Suzette Delaloge Journal: Am J Surg Date: 2003-02 Impact factor: 2.565
Authors: Laurien D C Hoefnagel; Marc J van de Vijver; Henk-Jan van Slooten; Pieter Wesseling; Jelle Wesseling; Pieter J Westenend; Joost Bart; Cornelis A Seldenrijk; Iris D Nagtegaal; Joost Oudejans; Paul van der Valk; Petra van der Groep; Elisabeth G E de Vries; Elsken van der Wall; Paul J van Diest Journal: Breast Cancer Res Date: 2010-09-23 Impact factor: 6.466